Reported net income attributable to Bristol Myers Squibb on a GAAP basis of $2.5 ... patients in the maintenance phase and expanding patient eligibility by reducing contraindications.

One such organisation is pharmaceutical company Bristol Myers Squibb (BMS ... This investment was in the form of coaching and mentoring from managers, upskilling opportunities, and site training ...

If a patient ... Bristol Myers Squibb’s business and market, particularly those identified in the cautionary statement and risk factors discussion in Bristol Myers Squibb’s Annual Report on ...

The CHMP of the EMA recommended approval of a new Opdivo formulation associated with a new route of administration (subcutaneous use), a new pharmaceutical form (solution for injection ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Sign up for our newsletter to get the latest on the ...

When I was diagnosed with cancer, I set out to understand why a single pill of Revlimid cost the same as a new iPhone. I’ve ...

Celgene drew on patent law, a drug safety system and even patient assistance programs to ... announced it had agreed to be acquired by Bristol Myers Squibb in a deal valued at $74 billion.

In 2003, Novartis acquired the worldwide adult medical nutrition business of Mead Johnson and Company, which is a subsidiary of Bristol-Myers Squibb, and also US biotech Idenix Pharmaceuticals ...

Events Rivaroxaban (number per 100 patient years) Warfarin (number ... Boehringer Ingelheim, Bristol-Myers Squibb, Eli-Lilly, GlaxoSmithKline, Johnson & Johnson, Pfizer and Sanofi.

consent form and any other written information provided to patients. Patients were evaluated by the investigators, and the data were collected and analysed by Bristol-Myers Squibb under the direction ...

Bristol Myers Squibb has appointed Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer, ...

uphold ethical business practices and champion patient voices," said Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers Squibb. "I am confident that under Cari’s ...